PTK/ZK as Post Transplant Maintenance Therapy in Patients With Multiple Myeloma

To evaluate the efficacy of PTK787/ZK 222584, in inducing at least a 50% reduction in paraprotein in patients with multiple myeloma whose paraprotein levels are \< 5 g/dL following high dose chemotherapy (HDCT) and Autologous Stem Cell Transplantation (ASCT). To assess the time to progression and disease free survival of patients treated with PTK787/ZK 222584. To assess the safety and tolerability of PTK787/ZK 222584 in multiple myeloma patients following ASCT.